This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Angel Eye adopts ZEISS AI retinal screening
Tech medical technology adoption

Angel Eye adopts ZEISS AI retinal screening

Analysis based on 7 articles · First reported Jun 03, 2026 · Last updated Jun 03, 2026

Sentiment
60
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The adoption of AI-assisted retinal screening by Angel Eye and Cataract Centre signifies a positive trend in the healthcare industry towards technological integration, potentially boosting demand for medical device companies like Zeiss (company). This move could lead to improved patient outcomes and more efficient clinical workflows, setting a precedent for other ophthalmology centers.

Healthcare Medical Devices Artificial Intelligence
Event Summary

Angel Eye and Cataract Centre in Singapore has integrated the ZEISS CIRRUS PathFinder, an AI-assisted retinal imaging system, into its cataract assessment workflow. This technology analyzes retinal and macular scans to aid in pre-surgical evaluation and treatment planning, aiming to reduce the risk of overlooking clinically relevant details. The adoption reflects a broader trend towards AI-supported ophthalmology tools to manage increasing demand for cataract care in ageing populations, particularly in Singapore. Dr Allan Fong, Medical Director of Angel Eye and Cataract Centre, completed an 'AI for Healthcare' program, underscoring the clinic's commitment to leveraging AI for improved patient care and streamlined appointments.

Entities Involved
priv
Angel Eye and Cataract Centre
Angel Eye and Cataract Centre adopted the ZEISS CIRRUS PathFinder, enhancing its cataract assessment workflow with AI-assisted retinal imaging, which is expected to improve patient care and operational efficiency.
Importance 90.0 Sentiment 70.0
per
Allan Fong
Dr Allan Fong, Medical Director of Angel Eye and Cataract Centre, completed the 'AI for Healthcare' programme and is actively using the ZEISS CIRRUS PathFinder, demonstrating his leadership in integrating advanced technology for patient care.
Importance 80.0 Sentiment 60.0
priv
Zeiss (company)
Zeiss (company)'s product, the ZEISS CIRRUS PathFinder, was adopted by Angel Eye and Cataract Centre, demonstrating the continued market penetration and utility of its AI-assisted ophthalmology tools.
Importance 70.0 Sentiment 50.0
cnt
Singapore
Singapore is highlighted as a region with increasing demand for cataract care in ageing populations, making the adoption of AI-supported ophthalmology tools like the ZEISS CIRRUS PathFinder particularly relevant for its healthcare sector.
Importance 40.0 Sentiment 20.0
oth
NUS Yong Loo Lin School of Medicine
NUS Yong Loo Lin School of Medicine provided the 'AI for Healthcare' programme, which Dr Allan Fong completed, indicating its role in educating medical professionals on AI applications in healthcare.
Importance 20.0 Sentiment 10.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.